We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Panretinal Photocoagulation vs Anti–Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy—Reply

Jeffrey G. Gross, MD1; Adam R. Glassman, MS2
[+] Author Affiliations
1Carolina Retina Center, Columbia, South Carolina
2Jaeb Center for Health Research, Tampa, Florida
JAMA Ophthalmol. 2016;134(6):716. doi:10.1001/jamaophthalmol.2016.0703.
Text Size: A A A
Published online


In Reply Singh and Singh state that the development or worsening of TRD as a result of preretinal fibrosis is a potential complication of anti-VEGF therapy in the setting of PDR based on description from a few case series or retrospective reports. Eyes with PDR are inherently at risk for developing TRD or having preexisting TRD worsen and threaten detachment of the macula. There is evidence, however, that anti-VEGF therapy does not increase the risk of this complication. In several randomized clinical trials using anti-VEGF treatment in eyes with PDR in the setting of diabetic macular edema or vitreous hemorrhage,13 rates of TRD have been similar or lower in the anti-VEGF group compared with a control group not receiving anti-VEGF therapy. In the current randomized clinical trial referenced by Singh and Singh, rates of TRD, rhegmatogenous retinal detachments, or combined tractional and rhegmatogenous retinal detachments were 6% in the anti-VEGF group and 10% in the PRP group.4 To our knowledge, there are no randomized clinical trials supporting the concern that anti-VEGF therapy for PDR is harmful. Although Singh and Singh raise the concern that eyes with PDR have the potential for severe vison loss with anti-VEGF use, severe vision loss did not occur at a higher rate in eyes assigned to ranibizumab compared with eyes assigned to PRP in the referenced study.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2016
Simar Rajan Singh, MS; Ramandeep Singh, MS
1Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
JAMA Ophthalmol. 2016;134(6):715-716. doi:10.1001/jamaophthalmol.2016.0701.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...